A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®.
Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal cancer within one year.
Read more on background, methodology and results of the study. Note: This abstract is available in German only please contact Abviris direct for assistance in English.
study tumour marker HIV patients